Background The association between coronavirus infection 2019 (COVID-19) and
thrombosis has been explicitly shown through numerous reports that demonstrate high rates …

Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with
a high incidence of thrombotic events during hospitalization; however, data examining rates …

Background Several observational studies have reported the rate of venous and arterial
thrombotic events in patients infected with COVID-19, with conflicting results. The aim of this …

Introduction: Thrombosis and bleeding are recognized complications of the novel
coronavirus infection (COVID-19), with a higher incidence described particularly in the …

This study describes demographics, thrombotic and bleeding events, mortality, and
anticoagulant use among hospitalized patients with COVID-19 in the United States. Premier …

Emerging evidence shows that the recent pandemic of coronavirus disease 19 (COVID-19)
is characterized by coagulation activation and endothelial dysfunction. This increases the …

Thromboprophylaxis/anticoagulation treatment is often required in hospitalized COVID-19
patients. We aimed to estimate the prevalence of major bleeding events in hospitalized …

Introduction In the first wave, thrombotic complications were common in COVID-19 patients.
It is unknown whether state-of-the-art treatment has resulted in less thrombotic complications …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with high rates of
thromboembolic events in hospitalized patients. It remains to be determined if this risk …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …